The Food and Drug Administration issued Ozempic Zepbound eye risk warnings on Monday, saying GLP-1 drugs may carry a potential risk of non-arteritic anterior ischemic optic neuropathy. The agency also required pharma companies to inform patients and doctors of the risk.
That condition, known as NAION, is sometimes called an eye stroke. It is caused by insufficient blood flow to the optic nerve and can lead to sudden vision loss and blindness in severe cases.
Ozempic and Wegovy
The warning reaches Novo Nordisk's Ozempic and Wegovy, along with Eli Lilly's Mounjaro and Zepbound. All four are GLP-1 drugs, a class that has exploded in popularity for its potent weight loss effects.
The FDA's action means the companies behind those drugs must update what patients and doctors are told about the risk. For a medication class used so widely, that change puts a rare complication in front of the people who prescribe it and the people who take it.
Mounjaro and Zepbound
NAION is rare, but the warning matters because the condition can be severe and there are currently no proven treatments. The FDA's decision also reflects a broader reality about GLP-1 drugs: side effects can appear in real-world use even when they were not observed in clinical trials.
For patients and doctors using Ozempic, Wegovy, Mounjaro and Zepbound, the practical change is straightforward. The risk now has to be part of the information they receive, so any new prescription discussion can include NAION alongside the drugs' weight-loss benefits.
FDA and NAION
The remaining question is how large the risk is for users of GLP-1 drugs compared with users who do not take them. The warning places that issue in the open, but the current step is the same: patients and doctors should expect the risk to be part of the conversation now.
